The Avenues Transitional Care Center | |
2043 19th Avenue, San Francisco, California 94116 | |
(415) 661-8787 | |
Name | The Avenues Transitional Care Center |
---|---|
Location | 2043 19th Avenue, San Francisco, California |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 140 |
Occupancy Rate | 61.43% |
Medicare ID (CCN) | 055963 |
Legal Business Name | Asjk Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1306360987 |
Organization Name | ASJK, LLC |
Doing Business As | THE AVENUES TRANSITIONAL CARE CENTER |
Address | 2043 19th Ave, San Francisco, CA 94116 |
Phone Number | 415-661-8787 |
News Archive
A new study in Biological Psychiatry reports that esketamine, a component of the general anesthetic ketamine, shows rapid and significant improvement in depressive symptoms in patients who do not respond to currently available therapies.
Age-related macular degeneration is the leading cause of blindness in older adults, yet researchers are still in the dark about many of the factors that cause this incurable disease.
In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.
A new study utilizes dynamic causal modeling to predict the effects of letting SARS-CoV-2 sweep through a largely vaccinated population.
Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.
› Verified 7 days ago
NPI Number | 1427072016 |
Organization Name | HILLHAVEN - MSC PARTNERSHIP |
Doing Business As | KINDRED NURSING AND REHABILITATION-NINETEENTH AVENUE |
Address | 2043 19th Ave, San Francisco, CA 94116 |
Phone Number | 415-661-8787 |
News Archive
A new study in Biological Psychiatry reports that esketamine, a component of the general anesthetic ketamine, shows rapid and significant improvement in depressive symptoms in patients who do not respond to currently available therapies.
Age-related macular degeneration is the leading cause of blindness in older adults, yet researchers are still in the dark about many of the factors that cause this incurable disease.
In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.
A new study utilizes dynamic causal modeling to predict the effects of letting SARS-CoV-2 sweep through a largely vaccinated population.
Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
A new study in Biological Psychiatry reports that esketamine, a component of the general anesthetic ketamine, shows rapid and significant improvement in depressive symptoms in patients who do not respond to currently available therapies.
Age-related macular degeneration is the leading cause of blindness in older adults, yet researchers are still in the dark about many of the factors that cause this incurable disease.
In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.
A new study utilizes dynamic causal modeling to predict the effects of letting SARS-CoV-2 sweep through a largely vaccinated population.
Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 10.45 | 14.46 |
Percentage of long-stay residents who lose too much weight | 11.11 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 14.49 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.67 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.12 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.32 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.51 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 7.51 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0.55 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 25.53 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 2.99 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 8.37 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 84.05 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 99.86 | 82.93 |
News Archive
A new study in Biological Psychiatry reports that esketamine, a component of the general anesthetic ketamine, shows rapid and significant improvement in depressive symptoms in patients who do not respond to currently available therapies.
Age-related macular degeneration is the leading cause of blindness in older adults, yet researchers are still in the dark about many of the factors that cause this incurable disease.
In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.
A new study utilizes dynamic causal modeling to predict the effects of letting SARS-CoV-2 sweep through a largely vaccinated population.
Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.
› Verified 7 days ago
Jewish Home & Rehab Center D/p Snf Location: 302 Silver Avenue, San Francisco, California 94112 Phone: (415) 334-2500 | |
Lawton Skilled Nursing & Rehabilitation Center Location: 1575 7th Avenue, San Francisco, California 94122 Phone: (415) 566-1200 | |
Central Gardens Post Acute Location: 1355 Ellis Street, San Francisco, California 94115 Phone: (415) 567-2967 | |
Victorian Post Acute Location: 2121 Pine Street, San Francisco, California 94115 Phone: (415) 922-5085 | |
The Avenues Transitional Care Center Location: 2043 19th Avenue, San Francisco, California 94116 Phone: (415) 661-8787 | |
Sequoias San Francisco Convalescent Hospital Location: 1400 Geary Blvd, San Francisco, California 94109 Phone: (415) 922-9700 |